The multifaceted role of the mineralocorticoid receptor in cancers

Tram B Doan; J Dinny Graham

doi:10.1016/j.jsbmb.2024.106541

The multifaceted role of the mineralocorticoid receptor in cancers

J Steroid Biochem Mol Biol. 2024 May 5:242:106541. doi: 10.1016/j.jsbmb.2024.106541. Online ahead of print.

Authors

Tram B Doan¹, J Dinny Graham²

Affiliations

¹ Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia.
² Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia; Westmead Breast Cancer Institute, Westmead Hospital, Westmead, NSW 2145, Australia. Electronic address: Dinny.Graham@sydney.edu.au.

PMID: 38714226
DOI: 10.1016/j.jsbmb.2024.106541

Abstract

The mineralocorticoid receptor (MR/NR3C2) is a member of the family of steroid receptors (SR) which also includes the estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and glucocorticoid receptor (GR). They function primarily as nuclear receptors to regulate gene expression. While the other steroid hormone receptors are known to play important roles in the pathogenesis and progression of many cancers, relatively little is understood about the role of MR in cancer biology. This review focuses on examining new insights into the potential roles and mechanisms of action of MR in cancers.

Keywords: Cancer; Mineralocorticoid receptor; Steroids.